Multiple myeloma in the very elderly patient: challenges and solutions
Open Access
- 31 December 2015
- journal article
- review article
- Published by Informa UK Limited in Clinical Interventions in Aging
- Vol. 11, 423-435
- https://doi.org/10.2147/CIA.S89465
Abstract
Diagnosis and management of myeloma in the very elderly patient is challenging. Treatment options have vastly improved for elderly myeloma patients but still require the clinician to personalize therapy. In this paper, we offer evidence-based, pragmatic advice on how to overcome six of the main challenges likely to arise: 1) diagnosis of myeloma in this age group, 2) assessment of the need for treatment, and the fitness for combination chemotherapy, 3) provision of the best quality of supportive care, 4) choice of combination chemotherapy in those fit enough for it, 5) treatment of relapsed myeloma, and 6) provision of end of life care. With an increased burden of comorbidities and a reduced resilience to treatment and its associated toxicities, the management of myeloma in this age group requires a different approach to that in younger patients to maximize both quality and length of life.Keywords
This publication has 52 references indexed in Scilit:
- Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 studyBlood, 2014
- Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved SurvivalJournal of Clinical Oncology, 2014
- Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority studyThe Lancet Oncology, 2011
- Multiple MyelomaNew England Journal of Medicine, 2011
- Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trialThe Lancet Oncology, 2010
- Treatment of Relapsed/Refractory Multiple MyelomaSeminars in Hematology, 2009
- Prevention of thalidomide- and lenalidomide-associated thrombosis in myelomaLeukemia, 2007
- Tolerance to chemotherapy in elderly patients with cancer.Cancer Control, 2007
- Use of comprehensive geriatric assessment in older cancer patients:Critical Reviews in Oncology/Hematology, 2005
- International Staging System for Multiple MyelomaJournal of Clinical Oncology, 2005